estriol has been researched along with Multiple Sclerosis in 14 studies
hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone
chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Animal models of multiple sclerosis have shown that the pregnancy hormone, estriol, can ameliorate disease and can cause an immune shift." | 9.10 | Treatment of multiple sclerosis with the pregnancy hormone estriol. ( Bouvier, S; Klutch, R; Liva, SM; Odesa, S; Pfeiffer, P; Sicotte, NL; Voskuhl, RR; Wu, TC, 2002) |
| " Here, oral treatment with an estrogen unique to pregnancy (estriol) using an 8 mg dose to induce a mid-pregnancy blood estriol level reduced serum neurofilament light chain in nonpregnant MS women at mean age of 37 years." | 8.12 | Decreased neurofilament light chain levels in estriol-treated multiple sclerosis. ( Itoh, N; Kuhle, J; MacKenzie-Graham, A; Patel, K; Siddarth, P; Voskuhl, R, 2022) |
| "To evaluate the use of estriol in the treatment of experimental autoimmune encephalomyelitis (EAE) and other cell mediated autoimmune diseases." | 7.70 | Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis. ( Dalal, MA; Kim, S; Liva, SM; Verity, MA; Voskuhl, RR, 1999) |
| "Estriol treatment initiated after disease onset decreased cerebral cortex atrophy." | 5.91 | Neuroprotection in Cerebral Cortex Induced by the Pregnancy Hormone Estriol. ( Farkhondeh, V; Gao, JL; Herbig, PD; Itoh, N; Itoh, Y; MacKenzie-Graham, A; Meyer, CE; Ngo, KH; Nguyen, Q; Oberoi, MR; Padilla-Requerey, AA; Siddarth, P; Smith, AW; Voskuhl, RR, 2023) |
| " Animal models of multiple sclerosis have shown that the pregnancy hormone, estriol, can ameliorate disease and can cause an immune shift." | 5.10 | Treatment of multiple sclerosis with the pregnancy hormone estriol. ( Bouvier, S; Klutch, R; Liva, SM; Odesa, S; Pfeiffer, P; Sicotte, NL; Voskuhl, RR; Wu, TC, 2002) |
| " Here, oral treatment with an estrogen unique to pregnancy (estriol) using an 8 mg dose to induce a mid-pregnancy blood estriol level reduced serum neurofilament light chain in nonpregnant MS women at mean age of 37 years." | 4.12 | Decreased neurofilament light chain levels in estriol-treated multiple sclerosis. ( Itoh, N; Kuhle, J; MacKenzie-Graham, A; Patel, K; Siddarth, P; Voskuhl, R, 2022) |
| "To evaluate the use of estriol in the treatment of experimental autoimmune encephalomyelitis (EAE) and other cell mediated autoimmune diseases." | 3.70 | Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis. ( Dalal, MA; Kim, S; Liva, SM; Verity, MA; Voskuhl, RR, 1999) |
| "Currently, the cause of MS is unknown." | 2.48 | Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. ( Spence, RD; Voskuhl, RR, 2012) |
| "Estriol treatment initiated after disease onset decreased cerebral cortex atrophy." | 1.91 | Neuroprotection in Cerebral Cortex Induced by the Pregnancy Hormone Estriol. ( Farkhondeh, V; Gao, JL; Herbig, PD; Itoh, N; Itoh, Y; MacKenzie-Graham, A; Meyer, CE; Ngo, KH; Nguyen, Q; Oberoi, MR; Padilla-Requerey, AA; Siddarth, P; Smith, AW; Voskuhl, RR, 2023) |
| "Estriol was also found to alter the cytokine profile of T cells toward Th2 phenotype by up-regulating the production of IL-10 and inhibiting TNFalpha secretion of T cells." | 1.31 | Regulatory effects of estriol on T cell migration and cytokine profile: inhibition of transcription factor NF-kappa B. ( Halder, JB; Hong, J; Rivera, VM; Zang, YC; Zhang, JZ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Voskuhl, R | 1 |
| Kuhle, J | 1 |
| Siddarth, P | 2 |
| Itoh, N | 2 |
| Patel, K | 1 |
| MacKenzie-Graham, A | 3 |
| Meyer, CE | 1 |
| Smith, AW | 1 |
| Padilla-Requerey, AA | 1 |
| Farkhondeh, V | 1 |
| Itoh, Y | 2 |
| Gao, JL | 1 |
| Herbig, PD | 1 |
| Nguyen, Q | 1 |
| Ngo, KH | 1 |
| Oberoi, MR | 1 |
| Voskuhl, RR | 7 |
| Nekrasova, I | 1 |
| Shirshev, S | 1 |
| Ali, ES | 1 |
| Mangold, C | 1 |
| Peiris, AN | 1 |
| Brook, J | 1 |
| Kurth, F | 1 |
| Meyer, C | 1 |
| Montag, MJ | 1 |
| Wang, HJ | 1 |
| Elashoff, R | 1 |
| Gold, SM | 1 |
| Spence, RD | 1 |
| Sicotte, NL | 1 |
| Liva, SM | 2 |
| Klutch, R | 1 |
| Pfeiffer, P | 1 |
| Bouvier, S | 1 |
| Odesa, S | 1 |
| Wu, TC | 1 |
| Palaszynski, KM | 1 |
| Liu, H | 1 |
| Loo, KK | 1 |
| Tanzer, J | 1 |
| Correale, J | 1 |
| Arias, M | 1 |
| Gilmore, W | 1 |
| Kim, S | 1 |
| Dalal, MA | 1 |
| Verity, MA | 1 |
| Drew, PD | 1 |
| Chavis, JA | 1 |
| Zang, YC | 1 |
| Halder, JB | 1 |
| Hong, J | 1 |
| Rivera, VM | 1 |
| Zhang, JZ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition.[NCT01466114] | Phase 2 | 64 participants (Anticipated) | Interventional | 2011-10-31 | Recruiting | ||
| A Pilot Trial of Testosterone Treatment for Fatigue in Men With Multiple Sclerosis[NCT03000127] | Phase 2 | 0 participants (Actual) | Interventional | 2018-07-01 | Withdrawn (stopped due to Lack of funding) | ||
| A Combination Trial of Copaxone Plus Estriol in RRMS[NCT00451204] | Phase 2 | 158 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Safety and Tolerability of Oral Two-Doses Estroprogestins Associated With Interferon-Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis[NCT00151801] | Phase 2 | 200 participants | Interventional | 2002-05-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A confirmed relapse was defined as new neurological symptoms or worsening of pre-existing symptoms, lasting at least 48 hours in a subject who had been neurologically stable or improving in the previous 30 days, accompanied by objective change in the neurological examination (worsening of 0.5 points on the EDSS or worsening by 1.0 or more points on the pyramidal, cerebellar, brainstem or visual functional system scores), not due to fatigue alone and not associated with fever or infection. (NCT00451204)
Timeframe: 12 months
| Intervention | relapses per year (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 0.25 |
| Placebo Capsules Plus Copaxone Injections | 0.48 |
A confirmed relapse was defined as new neurological symptoms or worsening of pre-existing symptoms, lasting at least 48 hours in a subject who had been neurologically stable or improving in the previous 30 days, accompanied by objective change in the neurological examination (worsening of 0.5 points on the EDSS or worsening by 1.0 or more points on the pyramidal, cerebellar, brainstem or visual functional system scores), not due to fatigue alone and not associated with fever or infection. (NCT00451204)
Timeframe: 24 months
| Intervention | relapses per year (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 0.25 |
| Placebo Capsules Plus Copaxone Injections | 0.37 |
(NCT00451204)
Timeframe: 24 months
| Intervention | probability of relapse at 24 months (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 33.3 |
| Placebo Capsules Plus Copaxone Injections | 42.9 |
Met all criteria for relapse except not confirmed to have increase in EDSS by an independent examiner. (NCT00451204)
Timeframe: 12 months
| Intervention | relapses per year (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 0.33 |
| Placebo Capsules Plus Copaxone Injections | 0.61 |
Met all criteria for relapse except not confirmed to have increase in EDSS by an independent examiner. (NCT00451204)
Timeframe: 24 months
| Intervention | relapses per year (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 0.32 |
| Placebo Capsules Plus Copaxone Injections | 0.46 |
(NCT00451204)
Timeframe: 24 months
| Intervention | probability of relapse event at 24 mo (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 40.5 |
| Placebo Capsules Plus Copaxone Injections | 46.9 |
3 reviews available for estriol and Multiple Sclerosis
| Article | Year |
|---|---|
Estriol: emerging clinical benefits.
Topics: Administration, Intravaginal; Bone Density; Estriol; Estrogen Replacement Therapy; Female; Humans; I | 2017 |
Pregnancy and multiple sclerosis: from molecular mechanisms to clinical application.
Topics: Clinical Trials as Topic; Disease Susceptibility; Estriol; Female; Humans; Incidence; Multiple Scler | 2016 |
Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration.
Topics: Animals; Central Nervous System Diseases; Dihydrotestosterone; Disease Models, Animal; Encephalomyel | 2012 |
1 trial available for estriol and Multiple Sclerosis
| Article | Year |
|---|---|
Treatment of multiple sclerosis with the pregnancy hormone estriol.
Topics: Adolescent; Adult; Biomarkers; Cross-Over Studies; Estriol; Female; Humans; Hypersensitivity, Delaye | 2002 |
10 other studies available for estriol and Multiple Sclerosis
| Article | Year |
|---|---|
Decreased neurofilament light chain levels in estriol-treated multiple sclerosis.
Topics: Adult; Biomarkers; Estriol; Estrogens; Female; Humans; Intermediate Filaments; Multiple Sclerosis; P | 2022 |
Neuroprotection in Cerebral Cortex Induced by the Pregnancy Hormone Estriol.
Topics: Animals; Atrophy; Cerebral Cortex; Encephalomyelitis, Autoimmune, Experimental; Estriol; Female; Mic | 2023 |
Estriol in regulation of cell-mediated immune reactions in multiple sclerosis.
Topics: Adaptive Immunity; Adult; Cells, Cultured; Dose-Response Relationship, Drug; Estriol; Female; Humans | 2020 |
Estriol-mediated neuroprotection in multiple sclerosis localized by voxel-based morphometry.
Topics: Adult; Atrophy; Cognitive Dysfunction; Estriol; Female; Gray Matter; Humans; Magnetic Resonance Imag | 2018 |
Estriol treatment ameliorates disease in males with experimental autoimmune encephalomyelitis: implications for multiple sclerosis.
Topics: Analysis of Variance; Animals; Cell Culture Techniques; Cytokines; Disease Models, Animal; Encephalo | 2004 |
Estrogen effect in multiple sclerosis more nuanced than described.
Topics: Adipose Tissue; Adult; Age of Onset; Estradiol; Estriol; Estrogens; Female; Humans; Inflammation Med | 2008 |
Steroid hormone regulation of cytokine secretion by proteolipid protein-specific CD4+ T cell clones isolated from multiple sclerosis patients and normal control subjects.
Topics: CD4-Positive T-Lymphocytes; Cell Separation; Clone Cells; Cytokines; Dexamethasone; Estriol; Estrone | 1998 |
Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis.
Topics: Animals; Autoimmune Diseases; Brain; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experime | 1999 |
Female sex steroids: effects upon microglial cell activation.
Topics: Animals; Cells, Cultured; Estradiol; Estriol; Female; Gene Expression; Interferon-gamma; Lipopolysac | 2000 |
Regulatory effects of estriol on T cell migration and cytokine profile: inhibition of transcription factor NF-kappa B.
Topics: Adult; Case-Control Studies; Cell Movement; Cytokines; DNA-Binding Proteins; Estriol; Female; Humans | 2002 |